CAS: 3215-70-1; 4-[2-[6-[[2-(3,4-Dihydroxyphenyl)-2-Hydroxyethyl]Amino]Hexylamino]-1-Hydroxyethyl]Benzene-1,2-Diol
该化合物是一种选择性的β-2-肾紧张受体激动剂,主要用作治疗哮喘和其他阻塞性肺病的支气管,其主要优点包括迅速采取行动和持续的支气化合物消化,使其对急性救济和维护疗法都有效;乙型乙型苯丙胺对支气滑动肌肉表现出高度特殊性,与非选择性的激动剂相比,将心血管的副作用降到最低程度;各种配方,包括注射和口服形式,都提供了临床使用的灵活性;该化合物的稳定性和可预测的药用植物基能进一步提高其治疗效用;乙基苯丙烯因能够放松子光滑肌肉,也在透析中使用.
- 英文名称4-[2-[6-[[2-(3,4-Dihydroxyphenyl)-2-Hydroxyethyl]Amino]Hexylamino]-1-Hydroxyethyl]Benzene-1,2-Diol
- 中文名称海索那林
- IUPAC名称4-[2-[6-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol
- 其它别名Benzylalcohol, a,a'-[hexamethylenebis(iminomethylene)]bis[3,4-dihydroxy-(8CI); Broncholysin; Hexoprenaline; Ipradol; N,N'-Bis[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]hexamethylenediamine
- CAS编号3215-70-1
- MFCD编号:MFCD00867050
- FDA UNII编号:G9L6B3W684
- 分子式:C22H34N2O10S分子量:518.58
- 产品CID: 1311962
- 同类组份化合物CAS3215-70-1(free base)32266-10-7 (sulfate)4323-43-7 (HCl)
- 产品分类原料药 → 呼吸系统用药 → 平喘药
物理性质
MSDS等安全信息
合成工艺路线路线简述
📜5-<3.4-Dibenzyloxy-Phenyl>-Oxazolidon-(2),1,6-二氯己烷 反应生成海索那林
参考文献:Jokokosi,Kienori;Vatanabeh,Mitio;Nisimura,Makoto
标题:Jokokosi,Kienori;Vatanabeh,Mitio;Nisimura,Makoto
海关参考信息
- 2902600000-乙苯
2906210000-苄醇
2907210001-间苯二酚
2922110001-单乙醇胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人：BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.
专利号:US-8143437-B2
优先权日:2002-02-19
标题:Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
发明人：GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X
权利人:GALLOP MARK A; XIANG JIA-NING; YAO FENMEI; BHAT LAXMINARAYAN; ZHOU CINDY X; XENOPORT INC
摘要:The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods for synthesizing these 1-acyl-alkyl derivatives.
专利号:KR-101513003-B1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy compositions and applications
专利号:US-10814013-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Kirchhoff E, Schneider V, Pichler G, Reif P, Haas J, Joksch M, Mager C, Schmied C, Schöll W, Pichler-Stachl E, Gold D. Hexoprenaline Compared with Atosiban as Tocolytic Treatment for Preterm Labor. Geburtshilfe Frauenheilkd. 2022 Aug 10;82(8):852-858. doi: 10.1055/a-1823-0176.
2: Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597.
3: Mayer M, Minichmayr A, Klement F, Hroncek K, Wertaschnigg D, Arzt W, Wiesinger-Eidenberger G, Lechner E. Tocolysis with the β-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F108-11. doi: 10.1136/archdischild-2011-301030. Epub 2012 May 18.
合成参考文献
摘要:Hrubý K. [Comparison of the cost of treatment of premature labor with atosiban or beta-sympathomimetics from the perspective of the health care payer--a pharmacoeconomic model]. Ceska Gynekol. 2004 Mar;69(2):96–105.
参考文献:10.1016/s0167-5273(96)02831-8
摘要:Chao C, Chen W, Chen M, Lee Y. Torsade de pointes in a patient using usual dose of beta agonist therapy. International Journal of Cardiology. 1996 Dec;57(3):295–6. doi: 10.1016/s0167-5273(96)02831-8.
📝 需求与反馈
尽可能描述清楚需求与问题信息
